anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Objective:To explore the effect of vestibular rehabilitation exercise platform based on browser server(BS) mode on vertigo symptoms, balance ability and anxiety of vertigo patients. Methods:The clinical data of 110 patients with vertigo in our hospital were retrospectively analyzed. The patients who received routine vestibular rehabilitation exercise from March 2019 to may 2020 were set as the control group (55 cases), and the patients who received vestibular rehabilitation exercise platform guidance based on BS mode from June 2020 to December 2021 were set as the study group (55 cases). The scores of Fugl Meyer balance assessment scale(FMA), hospital anxiety and Depression Scale(had), vertigo disorder scale(DHI), quality of life scale(SF-36), vertigo visual analog scale(VAS), Berg Balance Scale(BBS), rehabilitation treatment effect and rehabilitation exercise compliance were compared between the two groups. Results:before rehabilitation exercise, there was no significant difference in the scores of DHI, VAS, FMA, BBS, had and SF-36 between the two groups(P>0.05). After 3 months of exercise, the scores of DHI, had and vas in the study group were lower than those in the control group, and the scores of FMA, BBS and SF-36 in the study group were higher than those in the control group(P<0.05). The excellent and good rate of rehabilitation efficacy and treatment compliance rate in the study group were higher than those in the control group(P<0.05). Conclusion:The vestibular rehabilitation exercise platform based on CS mode can improve the limb movement and balance ability of patients with vertigo, reduce the vertigo symptoms and psychological anxiety, and improve the rehabilitation treatment effect and compliance of patients.
This study investigated the respiratory activity in adult Wistar rats across different behavioral seizure severity induced by pentylenetetrazole (PTZ). Animals underwent surgery for electrodes implantation, allowing simultaneous EEG and diaphragm EMG (DIAEMG) recordings and the respiratory frequency and DIAEMG amplitude were measured. Seizures were acutely induced through PTZ injection and classified based on a pre-established score, with absence-like seizures (spike wave discharge (SWD) events on EEG) representing the lowest score. The respiratory activity was grouped into the different seizure severities. During absence-like and myoclonic jerk seizures, the breathing frequency decreased significantly (∼50% decrease) compared to pre- and post-ictal periods. Pronounced changes occurred with more severe seizures (clonic and tonic) with periods of apnea, especially during tonic seizures. Apnea duration was significantly higher in tonic compared to clonic seizures. Notably, during PTZ-induced tonic seizures the apnea events were marked by tonic DIAEMG contraction (tonic-phase apnea). In the majority of animals (5 out of 7) this was a fatal event in which the seizure-induced respiratory arrest preceded the asystole. In conclusion, we provide an assessment of the respiratory activity in the PTZ-induced acute seizures and showed that breathing dysfunction is more pronounced in seizures with higher severity.
Enrolled subjects were orally administered IBI351 with recommended dose on an empty stomach. Esomeprazole were administered orally.
The present invention relates to a computer implemented method for providing recommendations for managing stress to a user wearing a device comprising a physiological sensor, comprising the following steps:a. Receiving physiological data from the physiological sensor,b. Determining at least one personal health index at regular intervals based on the physiological data,c. Monitoring an evolution over time of the health index,d. Determining a recommendation on the intake of a nutritional supplement according to the evolution over time of the personal health index,e. displaying the recommendation to the user.The invention further relates to a kit comprising a nutritional supplement and an app which is designed to carry out such a method.
The gut microbiota plays a crucial role in postnatal growth, particularly in modulating the development of animals during their growth phase. In this study, we investigated the effects of antibiotic-induced dysbiosis of the gut microbiota on the growth of weaning rats by administering a non-absorbable antibiotic cocktail (ABX) in water for 4 weeks. ABX treatment significantly reduced body weight and feed intake in rats. Concurrently, ABX treatment decreased microbial abundance and diversity in rat ceca, predominantly suppressing microbes associated with bile salt hydrolase (BSH) activity. Furthermore, decreased appetite may be attributed to elevated levels of glucagon-like peptide-1 (GLP-1) in the serum, along with reduced neuropeptide Y (NPY) and increased cocaine and amphetamine-regulated transcript (CART) in the hypothalamus at the mRNA level. Importantly, concentrations of insulin-like growth factor 1 (IGF-1) and insulin-like growth factor 2 (IGF-2) were decreased in the serum and liver of antibiotic-treated rats. These alterations were associated with significant down-regulation of IGF-2 mRNA in the liver and significantly decreased farnesoid X receptor (FXR) protein expression and binding to the IGF-2 promoter. These results indicate that antibiotic-induced gut microbial dysbiosis not only impacts bile acid metabolism but also diminishes rat growth through the FXR-mediated IGF-2 pathway.
The treatment landscape of solid tumors has changed markedly in the last years. Molecularly targeted treatments and immunotherapies have been implemented and have, in many cancers, lowered the risk of relapse and prolonged survival. Patients with tumors harboring specific targetable molecular alterations or mutations are often of a younger age, and hence future fertility and family building can be important concerns in this group. However, there are great uncertainties regarding the effect of the new drugs on reproductive functions, including fertility, pregnancy and lactation and how young patients with cancers, both women and men should be advised. The goal with this review is to gather the current knowledge regarding oncofertility and the different novel therapies, including immune checkpoint inhibitors, antibody-drug conjugates, small molecules and monoclonal antibody targeted therapies. The specific circumstances and reproductive concerns in different patient groups where novel treatments have been broadly introduced are also discussed, including those with melanoma, lung, breast, colorectal and gynecological cancers. It is clear, that more awareness is needed regarding potential drug toxicity on reproductive tissues, and it is of essence that individuals are informed based on current expertise and on available fertility preservation methods.
Methods for generating a report of genomic and medical information associated with a patient are described. The methods may comprise, for example, receiving genomic testing data associated with the patient. The methods may comprise, for example, based on the genomic testing data, retrieving medical information including one or more potential clinical treatments for the patient. The methods may comprise, for example, determining that the medical information has at least some clinical significance to the patient. The methods may comprise, for example, based on at least a portion of the medical information having at least some clinical significance to the patient, generating patient-specific medical data. The methods may comprise, for example, determining at least one specific position to dispose the medical information on the report based on the patient- specific medical data and generating the report based on the determined at least one specific position.
The present invention provides a system, and method for medical analysis treatment. The system includes a computer system (100) for storing a plurality of databases. The databases maintain medical research data regarding analyte characteristics, and vitamin/nutrient characteristics. A first database maintains a plurality of analyte records, wherein each record holds information regarding a particular analyte that was determined from the results of testing a human test group. Each analyte record includes a low value, a high value, and a target value. A second database maintains a plurality of vitamin/nutrient records wherein each vitamin/nutrient record includes analytes associated with the particular vitamin/nutrient, and an analyte level indicative of vitamin/nutrient that may have supportive effect. The method matches an individual's bodily fluid laboratory results with the databases to identify supportive nutrient metabolic agents for each of the analytes within the lab report, potential negative drug reaction to each analyte as they pertain to the individual's analyte status.
Background: Maintaining optimal glycaemic control in type 2 diabetes (T2D) is difficult. Telemedicine has potential to support poorly controlled people with T2D in the achievement of glycaemic control if the telemedicine solution includes a telemonitoring component. However, only few telemonitoring solutions for non-insulin treated T2D exist. Therefore, the aim of this feasibility study is to evaluate the feasibility of two telemonitoring intervention designs for non-insulin treated T2D patients with an eye to identify the most suitable telemonitoring intervention for a future large-scale randomized trial.

Method: The trial will be conducted as a three-month randomized feasibility study in four municipalities in North Denmark with 15 participants from each municipality. Two different telemonitoring intervention designs will be tested. One intervention will include self-monitoring of blood glucose (SMBG) together with monitoring of sleep and mental health. The second intervention will include an identical setup but with the addition of blood pressure and activity monitoring. Two municipalities will be allocated to one intervention design, whereas the other two municipalities will be allocated to the second intervention design. Qualitative interviews with participants and clinicians will be conducted to gain insight into their experiences with and acceptance of the intervention designs and trial procedures (e.g., blood sampling and questionnaires). In addition, differences in direct intervention costs between the two alternative interventions will be evaluated.
PURPOSE: To obtain a skin external preparation excellent in skin whitening effect, good in both usability and safety, containing escinol and/or salt thereof (and tranexamic acid and/or arbutin). CONSTITUTION: This skin external preparation contains pref. 0.01-5.0wt.% of at least one kind selected from escinol of the formula (R<1> is H or OH; R<2> is pyranose residue) and salts thereof (and pref. 0.017.0wt.% of tranexamic acid and/or arbutin). The escinol is a triterpenoid-based saponin which is obtained by alkali decomposition of escin (a mixture of plural saponins) in the extract from the seeds of Aesculus hippocastanum to effect elimination of the acyl group of the escin. Escinol or a salt thereof has an effect of suppressing the production or activity of pigment cell-activating factors in the skin; as a result, suppressing the melanogenesis and abnormal proliferation of pigment cells.
The use of an N-alkylpiperazinealkanamide for preventing and/or limiting reperfusion damage upon reperfusion of an organ or muscular tissue, particularly in a patient undergoing thrombolysis or reperfusion of the heart after open heart surgery or after receiving a donor heart. The use of an N-alkylpiperazinealkanamide for preventing and/or limiting reperfusion damage upon reperfusion of a transplanted heart. The use of an N-alkylpiperazinealkanamide for storing a heart for transplantation for at least 24 hours in a cold cardioplegic solution. Compositions comprising an effective reperfusion damage preventing and/or limiting amount of an N-aryl-piperazinealkanamide derivative and optionally further comprising a thrombolytic agent and/or cyclodextrin or an ether derivative thereof. Processes for preparing such compositions. Novel N-alkylpiperazinealkanamide compounds and a process for preparing said compounds.
Patients receive cyclophosphamide 60 mg/kg IV over 2 hours on days -5 and -4. Patients also undergo TBI twice daily on days -3 to -1 for a total of 1200 cGY.
The utility model relates to a traditional Chinese medicine bath bag, which comprises a medicine bag and traditional Chinese medicines arranged in the medicine bag, wherein: the Chinese medicine in the medicine bag is in a layered structure, the top layer is a Chinese medicine flower layer, the middle layer is a Chinese mugwort layer, and the bottom layer is a Chinese medicine layer; the top end of the medicine bag is provided with a sewing component; the outer surface of the medicine bag is provided with a plastic film. The suture assembly comprises a suture thread which is sewn at the port of the medicine bag, a unsealable thread which is different from a non-unsealable thread in color or material is arranged in the suture thread, the end part of the unsealable thread is connected with a stay wire head, and the stay wire head and the unsealable thread are integrally designed. The particle size of the mugwort powder is 200-300 meshes. The size of the Chinese medicinal powder is 400-500 mesh. The medicine bag is made of non-woven fabric material. The Chinese medicinal flower layer is flos Rosae Rugosae, flos Pruni mume, and bitter orange flower and Carthami flos. The Chinese medicinal materials comprise radix astragali, fructus Hippophae, radix Rhodiolae, and Margarita powder. The utility model effectively solves the problems of single structure and lower quality of the bath bag, effectively distinguishes different traditional Chinese medicine components, meets different requirements, improves the quality of the bath bag, and is suitable for wide application.
Long COVID-19 symptoms are characterized by systemic deterioration of the entire body, leading to significant physiological and functional imbalances. Common symptoms may be related to decreased short-term or long-term exercise capacity resulting from organ tissue damage, such as myocardial and pulmonary dysfunction. Currently, even vaccines and medications cannot effectively address the long-term consequences of COVID-19. Exercise training has been proven to improve exercise capacity and quality of life during the recovery period for various chronic disease patients.

A total of 24 patients will be included in the study. Following informed consent and baseline testing, the participants will be randomized in a 1:1 fashion to receive a 4-week aerobic exercise training or attention control.The main objective is to assess the effects of a 4-week aerobic exercise training program on cardiopulmonary fitness and long COVID-19 symptom improvement. Secondary objectives include: to characterize baseline and intervention-related changes in quality of life, depression, anxiety, insomnia status and perceived stress status.
The present disclosure relates to generating field-specific health scores for a system of record. Record objects of a system of record corresponding to a data source provider may be accessed. Each record object may correspond to a record object type and have one or more object field-value pairs. Node profiles may be maintained. Each node profile may include one or more node field-value pairs. A subset of node field-value pairs of the node profiles with confidence scores greater than a threshold score may be identified. Node profiles having the subset of node field-value pairs may be identified. Node field-value pairs of the subset may be compared with corresponding object field-value pairs of the record objects. A field-specific health score for each field may be generated based on the comparison.
The invention discloses a lysostaphic complex enzyme oral cavity disinfectant and a preparation method thereof. The lysostaphic complex enzyme oral cavity disinfectant comprises the following components in parts by mass: 20-40 parts of lysostaphin, 21-41 parts of antibacterial peptide, 21-41 parts of chlorhexidine acetate, 31-42 parts of sorbitol, 21-31 parts of sodium dihydrogen phosphate and 21-30 parts of disodium hydrogen phosphate. The oral cavity disinfectant can be used for treating oral cavity diseases, has the advantages of remarkable curative effect and no alcohol and drug resistance. The invention further discloses a preparation method of the oral cavity disinfectant. The preparation method comprises the following steps: 1) dissolving the lysostaphin, the ntibacterial peptide and the hlorhexidine acetate into distilled water, stirring to completely dissolve the lysostaphin, the ntibacterial peptide and the hlorhexidine acetate; 2) dissolving sorbitol into distilled water, and stirring to completely dissolve the sorbitol; 3) dissolving the sodium dihydrogen phosphate and the disodium hydrogen phosphate into distilled water, and stirring to completely dissolve the sodium dihydrogen phosphate and the disodium hydrogen phosphate; and 4) uniformly mixing solutions obtained in the steps 1), 2) and 3), and then filling the mixed solution. The preparation method has the advantages of simple process and strong operability.
PURPOSE:To provide the subject material capable of maintaining the freshness of fresh perishables such as vegetables, fruits and flowers, etc., for a long period of time by carrying on a packaging material substrate an anti-microbial, freshness-maintaining agent prepared from the genus Cruciferae plant, the genus Allium plant, etc., as raw material and, if necessary, a specific freshness- maintaining agent. CONSTITUTION:An anti-microbial, freshness-maintaining agent prepared from the genus Cruciferae plant such as Wasabi japonica or Armoracia rustiana, the genus Allium plant such as Allium sativum or Allium tuberosum, etc., is, if necessary, combined with (A) a substance capable of absorbing ethylene (e.g. active carbon), (B) a substance capable of decomposing ethylene (e.g. a phthalocyanine compound), (C) a water-absorbing resin (e.g. a polyacrylic acid- series highly water absorbing resin) and (D) a far IR ray-radiating ceramic. The composition is blended e.g. with a raw material for packaging material, molded and carried one the same to provide the objective material.
Loss-of-function mutations have provided crucial insights into the immunoregulatory actions of Foxp3+ regulatory T cells (Tregs). By contrast, we know very little about the consequences of defects that amplify aspects of Treg function or differentiation. Here we show that mice heterozygous for an Ikbkb gain-of-function mutation develop psoriasis. Doubling the gene dose (IkbkbGoF/GoF) results in dactylitis, spondylitis, and characteristic nail changes, which are features of psoriatic arthritis. IkbkbGoF mice exhibit a selective expansion of Foxp3 + CD25+ Tregs of which a subset express IL-17. These modified Tregs are enriched in both inflamed tissues, blood and spleen, and their transfer is sufficient to induce disease without conventional T cells. Single-cell transcriptional and phenotyping analyses of isolated Tregs reveal expansion of non-lymphoid tissue (tissue-resident) Tregs expressing Th17-related genes, Helios, tissue-resident markers including CD103 and CD69, and a prominent NF-κB transcriptome. Thus, IKK2 regulates tissue-resident Treg differentiation, and overactivity drives dose-dependent skin and systemic inflammation.
Targeting a mean arterial pressure of 65 mmHg or higher and a systolic blood pressure of 90 mmHg or higher during surgery. The target is applied until discharge from the post-anesthesia care unit. If the patient is transported to the intensive care unit after surgery, not the post-anesthesia care unit, then the strategy is applied until the end of surgery.
Control group patients were not subjected to any block or local infiltration anesthesia (local anesthetic administration around the incision). Their postoperative pain was relieved with tramadol (intravenous analgesic drug) administration by using patient-controlled analgesia (PCA) device. Patient-controlled analgesia was achieved with tramadol hydrochloride at a concentration of 4 mg per 1 ml with the PCA device. The PCA device was configured to administer the patients boluses of 10 mg tramadol hydrochloride with a lockout time of 20 minutes, allowing a maximum of 4 pushes per hour. The total dose was standardized for all patients with a maximum daily dose of 400 mg and a maximum dose of 100 mg tramadol hydrochloride every 6 hours.
PURPOSE: A composition which includes Hirudo Nipponica Whitman extract is provided to be used for inhibiting an activation of tyrosinase; suppressing a melanogenesis; preventing, reducing and treating a disease from an excessive formation of the melanin; and whitening effect. CONSTITUTION: A cosmetic composition includes Hirudo Nipponica Whitman extracts as an active ingredient. The cosmetic composition is for whitening effect. The cosmetic composition has an antioxidant activity. The Hirudo Nipponica Whitman extract is selected from a group which comprises a methanol extract of Hirudo Nipponica Whitman and an ethanol extract of Hirudo Nipponica Whitman. The melanogenesis hindering medicinal composition includes the Hirudo Nipponica Whitman extract as the active ingredient.
Tavaborole topical solution, 5% contains tavaborole, 5% (w/w) in a clear, colorless alcohol-based solution for topical use. The active ingredient, tavaborole, is an oxaborole antifungal with the chemical name of 5-fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole. The chemical formula is C7H6BFO2, the molecular weight is 151.93 and the structural formula is: 

Tavaborole is a white to off-white powder. It is slightly soluble in water and freely soluble in ethanol and propylene glycol.

Each mL of tavaborole topical solution contains 43.5 mg of tavaborole. Inactive ingredients include alcohol (73.11% v/v), edetate calcium disodium, and propylene glycol.
The pregnant subjects in Control group are intervented with no drugs, but their newborns are given HBIG 200IU by injection immediately after born and at day 15. They are also injected with genetically engineered HB vaccine 20ug respectively at age of 0, 1 and 6 months.
A fluid delivery device is provided for transdermal delivery of fluid medications to patients. The device comprises a thin envelope which is applied to a patient's skin. The envelope comprises at least one diffusion layer coupled to at least one impermeable layer such that at least one chamber exists therebetween. Other embodiments include internal diffusion layers, and thus possess additional chambers, as well. The impermeable layer comprises a top surface of the device. A valve positioned in the impermeable layer facilitates filling the device with fluid, as well as connection of the device to external fluid sources such as an intravenous bag, pump, or other external fluid delivery system. The diffusion layer may comprise a semi-permeable membrane which controls the rate of fluid flow from the device to the patient's skin.
The invention discloses an ornidazole injection and a preparing method thereof. The metric injection volume of the ornidazole injection is 1-2 mL. The ornidazole concentration is 0.25-0.5 g/mL. The solvent of the injection is absolute ethyl alcohol or a mixture of absolute ethyl alcohol and glycerol. A finished product of the ornidazole injection is extremely low in impurity content, good in stability and extremely stable in guarantee period. Compared with originally developed ornidazole injections, the ornidazole injection provided by the invention is free of propylene glycol, and is better in clinical using safety, less in medical risk and simpler in preparation process.